Business · 18/10/2024Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Wavewriter Alpha Spinal Cord Stimulator System
Summary
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the Wavewriter Alpha Spinal Cord Stimulator System, following a patent extension application submitted to the US Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →